Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Comorbidome and short-term prognosis in hospitalised COPD patients: the ESMI study

Pere Almagro, Francisco Javier Cabrera, Jesus Diez-Manglano, Ramon Boixeda, Jesus Recio, Joan Mercade, Sergi Yun, Joan B. Soriano for the Working Group on COPD, Spanish Society of Internal Medicine
European Respiratory Journal 2015; DOI: 10.1183/09031936.00008015
Pere Almagro
1Internal Medicine Service, Hospital Universitario Mútua de Terrassa, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: 19908pam@comb.cat
Francisco Javier Cabrera
2Internal Medicine Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesus Diez-Manglano
3Internal Medicine Service, Hospital Royo Vilanova, Zaragoza, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramon Boixeda
4Internal Medicine Service, Hospital de Mataró, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesus Recio
5Internal Medicine Service, Hospital Universitario Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joan Mercade
1Internal Medicine Service, Hospital Universitario Mútua de Terrassa, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergi Yun
1Internal Medicine Service, Hospital Universitario Mútua de Terrassa, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joan B. Soriano
6Instituto de Investigación Sanitaria Princesa (IP), Universidad Autónoma de Madrid, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

A comorbidome is a useful representation of the prevalence and impact of comorbidities in hospitalised COPD patients http://ow.ly/KYzSF

To the Editor:

Chronic obstructive pulmonary disease (COPD) patients have an increased prevalence of cardiovascular disease, cancer or psychiatric diseases, among many other comorbid conditions. This is explained in part by smoking history, along with genetic factors, ageing and the low grade inflammation characteristic of COPD [1, 2]. Although comorbidities may be present at the time of the initial diagnosis, their frequency increases with COPD progression, and are particularly common in patients with more advanced disease, especially in those hospitalised with acute exacerbations [3, 4]. These comorbidities complicate the management of COPD patients, lengthen hospital stay, cause physical functional dependency, increase number of readmissions, and are associated with decreased survival in the short, medium and long term [4–6].

Divo et al. [7] recently reported that fifteen of 79 comorbidities studied were related with an increased mortality during follow-up. Based on the BODE cohort, these authors developed the COPD specific CO-morbidity TEst (COTE), a new comorbidity index similar to the Charlson index, alongside a graphic representation of prevalence and impact in mortality of these comorbidities mimicking the solar system, called “the COPD comorbidome” that visually conveys the prevalence of the disease (size of the circles) and the risk of death (proximity to the centre) [7, 8].

However, the BODE cohort included predominantly ambulatory patients with fewer comorbidities at the study inclusion, so that the representation of this comorbidome may be different in other populations, such as patients hospitalised for exacerbation of COPD in which the associated diseases are more prevalent and severe. Our main objective was to replicate the comorbidome in patients hospitalised for COPD exacerbation using data from the ESMI study [4].

In brief, ESMI is a longitudinal, observational, multicentre study conducted in 70 internal medicine services in Spain. Inclusion criteria were: 1) age 40 years and older, 2) admission for a COPD exacerbation, and 3) forced spirometry with a post-bronchodilator forced expiratory volume in 1 s (FEV1) <80% of predicted and an FEV1 to forced vital capacity ratio <0.70. Patients with a previous diagnosis of asthma or bronchiectasis as predominant disease, inability to perform spirometry or admission for reasons other than an exacerbation of COPD were excluded.

Comorbidity data were collected using the Charlson index, a standard scale with 15 chronic diseases graded for severity of disease. Additionally, other disorders and conditions were identified using a specific questionnaire that included several relevant chronic diseases not included in the Charlson index, such as depression, arterial hypertension, anaemia, arrhythmias or dyslipidaemia, among others. Also data on dyspnoea (modified Medical Research Council (mMRC) scale), functional status (Katz) and previous hospitalisations for COPD or other causes were collected. Finally, vital status and cause of death up to 3 months after discharge were assessed by the same investigators who treated the patients during index exacerbation and were responsible for subsequent monitoring.

Qualitative variables were expressed as absolute values and percentages, while quantitative variables were summarised as mean±sd. For time-dependent variables we used the Cox logistic regression and Kaplan− Meier statistics. The study was approved by the clinical investigation ethics committee of the Hospital Mútua de Terrassa, Barcelona, Spain (EO/0922_0709). All patients participated voluntarily and signed written informed consent forms. The comorbidome was plotted according to the original design of Divo et al. [7], using the size of the circles to express the prevalence in percentage of different comorbidities and the risk of death (proximity to the centre) based on the value of the hazard ratio.

Overall, 606 patients were included. Mean±sd age of the studied population patients was 72.6±9.9 years (range 41–94 years); 594 (89.9%) were men, with a mean±sd post-bronchodilator FEV1 of 43±21.2%. The average score on the Charlson index was 3.1±2. The most commonly observed comorbidities in this index were heart failure (32.8%), diabetes without complications (28.4%), and ischaemic heart disease (20.8%). Regarding comorbidities not included in the Charlson index, the most frequent were arterial hypertension (63.4%), osteoporosis (16%), abdominal obesity (29%), dyslipidaemia (34%), anaemia (19.3%), and psychological disorders: depression (15%) or anxiety (18.3%). Comorbidities with a prevalence greater than 10% or related with mortality are detailed in table 1.

View this table:
  • View inline
  • View popup
TABLE 1

Comorbidities and mortality: Cox regression analysis

27 patients (4.5%) died up to 3 months after discharge. The causes of death were respiratory failure in 17 cases, stroke in three, cardiovascular in two, cancer in two, and other causes in three. Mortality at 3 months was associated with age, number of hospital admissions in the previous year, greater dyspnoea (mMRC), chronic home oxygen therapy, more functional dependence (Katz index), and comorbidities both measured with the Charlson index and total of comorbidities. Several individual comorbidities were also associated with 3-month mortality, such as ischaemic heart disease, heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic kidney disease, depression or atrial fibrillation.

As shown in figure 1, the comorbidome in the ESMI study differs from that previously published by Divo et al. [7], reflecting differences between the studied populations with different patterns and impact of comorbidities. Depression is not associated with mortality in the BODE cohort, although in the ESMI study its prevalence was high and significantly associated with mortality, similar to the findings of previous studies performed in hospitalised COPD patients [6]. Of note, the comorbidity with greater impact in mortality at 3 months was dementia, although its prevalence in our study was very low (3.6%), probably reflecting a selection bias since all our patients met high quality spirometric criteria and it is well-known that many patients with dementia are not able to perform good quality spirometry [9–12].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

The area of the circle relates to the prevalence of the disease. The proximity to the centre (mortality) expresses the strength of the association between the disease and risk of death (hazard ratio). Bubble colours represent organ systems: 1) cardiovascular (red): arterial hypertension, ischaemic heart disease, atrial fibrillation, cardiac failure, peripheral artery disease, cerebrovascular disease; 2) metabolic disorders (brown): abdominal obesity, diabetes mellitus, dyslipidaemia, anaemia, chronic kidney failure, osteoporosis; 3) mental disorders (blue): depression, dementia, anxiety; 4) respiratory disease (green): obstructive sleep apnoea; 5) neoplasm (black).

The most frequent cause of death at 3 months in the ESMI study was respiratory failure, in spite of which several individual comorbidities are significantly related with mortality, reinforcing the importance of their combination in the individual patient prognosis. Indeed in many patients, COPD is just one more component of multiple comorbidities, and hence the term “multimorbidity” would be more accurate [13, 14].

A relevant difference and a probable limitation of our study compared with that previously published by Divo et al. [7] is the short follow-up time after discharge for COPD exacerbation (3 months). This is due mainly to the different objectives and thus differences in design between the two studies. The main purpose of the ESMI study was to explore prospectively comorbidities in COPD patients hospitalised for acute exacerbation in internal medicine services and to examine effects of them on short-term mortality. In contrast, the study of Divo et al. [7] was based on stable COPD outpatients, enrolled in pulmonary services with a lower comorbidity at inclusion and a longer follow-up, so the number and severity of comorbidities and their prognostic impact are clearly different. A second limitation is that inclusion and exclusion criteria in the ESMI study were necessarily restrictive in order to increase internal consistency so our results cannot be generalised to other populations.

In conclusion, our study reinforces the usefulness of a comorbidome as graphical representation of the prevalence and impact of comorbidities in patients hospitalised for COPD.

Footnotes

  • Support statement: The ESMI study was supported by Chiesi España. The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

  • Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

  • Received January 17, 2015.
  • Accepted March 17, 2015.
  • Copyright ©ERS 2015

References

  1. ↵
    1. Vanfleteren LE,
    2. Spruit MA,
    3. Groenen M, et al.
    Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728–735.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Faner R,
    2. Cruz T,
    3. López-Giraldo A, et al.
    Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775–788.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Soriano JB,
    2. Visick GT,
    3. Muellerova H, et al.
    Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099–2107.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Almagro P,
    2. Cabrera FJ,
    3. Diez J, et al.
    Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD. The ESMI study. Chest 2012; 142: 1126–1133.
    OpenUrlCrossRefPubMedWeb of Science
    1. Roberts CM,
    2. Stone RA,
    3. Lowe D, et al.
    Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD 2011; 8: 354–361.
    OpenUrlCrossRefWeb of Science
  5. ↵
    1. Almagro P,
    2. Calbo E,
    3. Ochoa de Echagüen A, et al.
    Mortality after hospitalization for COPD. Chest 2002; 121: 1441–1448.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Divo M,
    2. Cote C,
    3. de Torres JP, et al.
    Comorbidities and Risk of Mortality in Patients with COPD. Am J Respir Crit Care Med 2012; 186: 155–161.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Fabbri LM,
    2. Beghé B,
    3. Agustí A
    . COPD and the Solar System. Am J Respir Crit Care Med 2012; 186: 117–119.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Carvalhaes-Neto N,
    2. Lorino H,
    3. Gallinari C, et al.
    Cognitive function and assessment of lung function in the elderly. Am J Respir Crit Care Med 1995; 152: 1611–1615.
    OpenUrlCrossRefPubMedWeb of Science
    1. Allen SC,
    2. Baxter M
    . A comparison of four tests of cognition as predictors of inability to perform spirometry in old age. Age Ageing 2009; 38: 537–541.
    OpenUrlAbstract/FREE Full Text
    1. Allen SC,
    2. Yeung P
    . Inability to draw intersecting pentagons as a predictor of unsatisfactory spirometry technique in elderly hospital inpatients. Age Ageing 2006; 35: 304–306.
    OpenUrlFREE Full Text
  9. ↵
    1. Dodd JW,
    2. Charlton RA,
    3. van den Broek MD, et al.
    Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. Chest 2013; 144: 119–127.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Clini EM,
    2. Beghé B,
    3. Fabbri LM
    . Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD. Am J Respir Crit Care Med 2013; 187: 668–671.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. J Am Geriatr Soc 2012; 60: E1–E25.
    OpenUrlCrossRefPubMed
View Abstract
Next
Back to top
View this article with LENS
Vol 62 Issue 3 Table of Contents
European Respiratory Journal: 62 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comorbidome and short-term prognosis in hospitalised COPD patients: the ESMI study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Comorbidome and short-term prognosis in hospitalised COPD patients: the ESMI study
Pere Almagro, Francisco Javier Cabrera, Jesus Diez-Manglano, Ramon Boixeda, Jesus Recio, Joan Mercade, Sergi Yun, Joan B. Soriano
European Respiratory Journal Apr 2015, ERJ-00080-2015; DOI: 10.1183/09031936.00008015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Comorbidome and short-term prognosis in hospitalised COPD patients: the ESMI study
Pere Almagro, Francisco Javier Cabrera, Jesus Diez-Manglano, Ramon Boixeda, Jesus Recio, Joan Mercade, Sergi Yun, Joan B. Soriano
European Respiratory Journal Apr 2015, ERJ-00080-2015; DOI: 10.1183/09031936.00008015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
  • A rare pulmonary zygomycosis manifested as chronic mediastinitis and bronchial perforation
  • Pulmonary endarterectomy in sickle cell haemoglobin C disease
Show more Letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society